Lexaria Bioscience Confirms Nasdaq Listing for Stock & Warrants
Ticker: LEXX · Form: 8-K · Filed: Jan 24, 2024
Sentiment: neutral
Topics: regulatory-filing, exchange-listing, compliance
TL;DR
**Lexaria Bioscience just confirmed its stock and warrants are still trading on Nasdaq.**
AI Summary
Lexaria Bioscience Corp. filed an 8-K on January 24, 2024, primarily to disclose its common stock and warrants are registered on The Nasdaq Capital Market under symbols LEXX and LEXXW, respectively. This filing, categorized under Regulation FD Disclosure and Financial Statements and Exhibits, confirms the company's compliance with SEC reporting requirements. For investors, this matters because it reaffirms Lexaria's listing on a major exchange, providing liquidity and transparency, which are crucial for stock valuation and investor confidence.
Why It Matters
This filing confirms Lexaria Bioscience Corp.'s continued listing on The Nasdaq Capital Market, which is important for maintaining investor confidence and ensuring liquidity for its common stock and warrants.
Risk Assessment
Risk Level: low — This filing is a routine disclosure confirming existing exchange listings and does not introduce new financial or operational risks.
Analyst Insight
A smart investor would view this as a routine compliance filing, confirming the company's status on a major exchange, which is a positive for liquidity and transparency but doesn't signal new operational developments or financial changes. No immediate action is warranted based solely on this filing.
Key Numbers
- $0.001 — par value per share (This is the stated par value for Lexaria Bioscience Corp.'s common stock.)
Key Players & Entities
- Lexaria Bioscience Corp. (company) — the registrant filing the 8-K
- The Nasdaq Capital Market (company) — the exchange where Lexaria's securities are registered
- LEXX (company) — trading symbol for Lexaria's Common Stock
- LEXXW (company) — trading symbol for Lexaria's Warrants to Purchase Common Stock
- $0.001 (dollar_amount) — par value per share of Common Stock
Forward-Looking Statements
- Lexaria Bioscience Corp. will maintain its listing on The Nasdaq Capital Market. (Lexaria Bioscience Corp.) — high confidence, target: 2025-01-24
FAQ
What is the primary purpose of this 8-K filing by Lexaria Bioscience Corp.?
The primary purpose of this 8-K filing, dated January 24, 2024, is to disclose information under Regulation FD Disclosure and Financial Statements and Exhibits, specifically confirming that Lexaria Bioscience Corp.'s Common Stock and Warrants to Purchase Common Stock are registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.
On which exchange are Lexaria Bioscience Corp.'s securities registered?
Lexaria Bioscience Corp.'s Common Stock and Warrants to Purchase Common Stock are registered on The Nasdaq Capital Market.
What are the trading symbols for Lexaria Bioscience Corp.'s registered securities?
The trading symbol for Lexaria Bioscience Corp.'s Common Stock is LEXX, and the trading symbol for its Warrants to Purchase Common Stock is LEXXW.
What is the par value per share of Lexaria Bioscience Corp.'s Common Stock?
The par value per share of Lexaria Bioscience Corp.'s Common Stock is $0.001.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 24, 2024.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-01-24 14:12:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
Filing Documents
- lxrp_8k.htm (8-K) — 23KB
- lxrp_ex991.htm (EX-99.1) — 68KB
- lxrp_ex991img9.jpg (GRAPHIC) — 42KB
- lxrp_ex991img10.jpg (GRAPHIC) — 20KB
- lxrp_ex991img11.jpg (GRAPHIC) — 19KB
- lxrp_ex991img12.jpg (GRAPHIC) — 1KB
- 0001640334-24-000137.txt ( ) — 345KB
- lxrp-20240124.xsd (EX-101.SCH) — 6KB
- lxrp-20240124_lab.xml (EX-101.LAB) — 14KB
- lxrp-20240124_cal.xml (EX-101.CAL) — 1KB
- lxrp-20240124_pre.xml (EX-101.PRE) — 9KB
- lxrp-20240124_def.xml (EX-101.DEF) — 2KB
- lxrp_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure Christopher Bunka, the Chief Executive Officer of Lexaria Bioscience Corp. ("Lexaria") has issued a letter discussing Lexaria's strategic outlook and summarizing its accomplishments during the 2023 year. A copy of the letter is attached as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits 99.1 Letter from the CEO 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Chris Bunka Chris Bunka CEO, Principal Executive Officer Date: January 24, 2024 3